John D. Groarke MBBCh, MPH , Kirsten K. Ness PT, PhD , Rikeenkumar Dhaduk , Juan C. Plana MD , Jean Bernard Durand MD , Russell V. Luepker MD, MS , Vijaya M. Joshi MD , Matthew Ehrhardt MD , Daniel A. Mulrooney MD , Stephanie B. Dixon MD , Anju Nohria MD , Daniel M. Green MD , Rebecca M. Howell PhD , Deo Kumar Srivastava PhD , John L. Jefferies MD, MPH , Leslie L. Robison PhD , Melissa M. Hudson MD , Gregory T. Armstrong MD, MSCE
{"title":"Autonomic Dysfunction Among Adult Survivors of Childhood Cancer in the St. Jude Lifetime Cohort Study","authors":"John D. Groarke MBBCh, MPH , Kirsten K. Ness PT, PhD , Rikeenkumar Dhaduk , Juan C. Plana MD , Jean Bernard Durand MD , Russell V. Luepker MD, MS , Vijaya M. Joshi MD , Matthew Ehrhardt MD , Daniel A. Mulrooney MD , Stephanie B. Dixon MD , Anju Nohria MD , Daniel M. Green MD , Rebecca M. Howell PhD , Deo Kumar Srivastava PhD , John L. Jefferies MD, MPH , Leslie L. Robison PhD , Melissa M. Hudson MD , Gregory T. Armstrong MD, MSCE","doi":"10.1016/j.jaccao.2024.08.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The burden and functional significance of autonomic dysfunction among survivors of childhood cancer is unknown.</div></div><div><h3>Objectives</h3><div>We evaluated the prevalence, risk factors, and functional relevance of autonomic dysfunction in survivors.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional prospective evaluation of 1,041 adult survivors of childhood cancer treated with anthracyclines (31.1%), chest-directed radiation (13.5%), both (19.5%), or neither (35.9%), and 286 community control subjects enrolled in the SJLIFE (St Jude Lifetime Cohort Study). Four measures of autonomic dysfunction were evaluated: elevated resting heart rate, decreased heart rate reserve, decreased systolic blood pressure response to exercise, and delayed heart rate recovery. Logistic regression tested associations with impaired cardiorespiratory fitness (peak V<span>o</span><sub>2</sub> < 80% predicted).</div></div><div><h3>Results</h3><div>Survivors (50.7% female) were 9.0 ± 5.8 years at cancer diagnosis and 35.5 ± 8.9 years at evaluation. Prevalence (survivors vs control subjects) of elevated resting heart rate (17.9% vs 7.0%), decreased heart rate reserve (21.7% vs 9.1%), decreased systolic blood pressure response to exercise (25.3% vs 12.6%), and delayed heart rate recovery (24.3% vs 10.6%) was more than 2-fold higher among survivors (<em>P</em> < 0.001 for all). Carboplatin (adjusted OR: 2.50; 95% CI: 1.42-4.40; <em>P</em> = 0.001), chest-directed radiation therapy (adjusted OR: 2.06; 95% CI: 1.52-2.75; <em>P</em> < 0.001), and cranial radiation (adjusted OR: 1.49; 95% CI: 1.08-2.05; <em>P</em> = 0.015) were associated with an increased likelihood of having ≥2 measures of autonomic dysfunction. Survivors with ≥2 measures of autonomic dysfunction were at increased risk for impaired cardiorespiratory fitness (adjusted OR: 2.71; 95% CI: 1.82-4.02; <em>P</em> < 0.001).</div></div><div><h3>Conclusions</h3><div>Survivors of childhood cancer manifest a higher prevalence of autonomic dysfunction associated with impaired cardiorespiratory fitness.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 775-787"},"PeriodicalIF":12.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jacc: Cardiooncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666087324002825","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
The burden and functional significance of autonomic dysfunction among survivors of childhood cancer is unknown.
Objectives
We evaluated the prevalence, risk factors, and functional relevance of autonomic dysfunction in survivors.
Methods
We conducted a cross-sectional prospective evaluation of 1,041 adult survivors of childhood cancer treated with anthracyclines (31.1%), chest-directed radiation (13.5%), both (19.5%), or neither (35.9%), and 286 community control subjects enrolled in the SJLIFE (St Jude Lifetime Cohort Study). Four measures of autonomic dysfunction were evaluated: elevated resting heart rate, decreased heart rate reserve, decreased systolic blood pressure response to exercise, and delayed heart rate recovery. Logistic regression tested associations with impaired cardiorespiratory fitness (peak Vo2 < 80% predicted).
Results
Survivors (50.7% female) were 9.0 ± 5.8 years at cancer diagnosis and 35.5 ± 8.9 years at evaluation. Prevalence (survivors vs control subjects) of elevated resting heart rate (17.9% vs 7.0%), decreased heart rate reserve (21.7% vs 9.1%), decreased systolic blood pressure response to exercise (25.3% vs 12.6%), and delayed heart rate recovery (24.3% vs 10.6%) was more than 2-fold higher among survivors (P < 0.001 for all). Carboplatin (adjusted OR: 2.50; 95% CI: 1.42-4.40; P = 0.001), chest-directed radiation therapy (adjusted OR: 2.06; 95% CI: 1.52-2.75; P < 0.001), and cranial radiation (adjusted OR: 1.49; 95% CI: 1.08-2.05; P = 0.015) were associated with an increased likelihood of having ≥2 measures of autonomic dysfunction. Survivors with ≥2 measures of autonomic dysfunction were at increased risk for impaired cardiorespiratory fitness (adjusted OR: 2.71; 95% CI: 1.82-4.02; P < 0.001).
Conclusions
Survivors of childhood cancer manifest a higher prevalence of autonomic dysfunction associated with impaired cardiorespiratory fitness.
期刊介绍:
JACC: CardioOncology is a specialized journal that belongs to the esteemed Journal of the American College of Cardiology (JACC) family. Its purpose is to enhance cardiovascular care for cancer patients by publishing high-quality, innovative scientific research and sharing evidence-based knowledge.
The journal aims to revolutionize the field of cardio-oncology and actively involve and educate professionals in both cardiovascular and oncology fields. It covers a wide range of topics including pre-clinical, translational, and clinical research, as well as best practices in cardio-oncology. Key areas of focus include understanding disease mechanisms, utilizing in vitro and in vivo models, exploring novel and traditional therapeutics (across Phase I-IV trials), studying epidemiology, employing precision medicine, and investigating primary and secondary prevention.
Amyloidosis, cardiovascular risk factors, heart failure, and vascular disease are some examples of the disease states that are of particular interest to the journal. However, it welcomes research on other relevant conditions as well.